LSR Stock Chart & Stats
€1.31
€0.00(0.00%)
At close: 4:00 PM EDT
€1.31
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.76 - €9.70
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€32.65M
Enterprise Value€13.97
Total Cash (Recent Filing)€6.53M
Total Debt (Recent Filing)€7.89M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Dec 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-2.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.81
Revenue Forecast (FY)€16.75M
Bulls Say, Bears Say
Bulls Say
CDMO Revenue PlatformThe CDMO business provides an identifiable non-product revenue channel while Multikine remains investigational. Contract manufacturing and facility-access work can diversify the company’s funding base and create commercial capabilities that may remain useful as development programs advance.
Focused Immunotherapy PipelineA defined lead program gives Cel-Sci a focused path toward potential product commercialization rather than an unfocused research portfolio. If development succeeds, an approved therapy could add a recurring product revenue stream beyond the existing service business.
Historically Moderate LeverageThe historical balance sheet indicates that leverage was generally moderate for a development-stage biotech and that the company maintained positive equity through 2025. This provides a stronger prior capital structure than the latest volatility alone suggests, although execution remains important.
Bears Say
No Demonstrated Sales BaseZero reported revenue confirms that Cel-Sci remains pre-commercial and has not demonstrated product-market monetization. Without an established sales base, future operating scale depends on clinical progress, potential approval, and expansion of contract services rather than recurring product demand.
Persistent Cash BurnConsistently negative operating and free cash flow means the business is not self-funding. Continued spending on development and operations therefore requires additional financial resources, which can constrain strategic flexibility and increase dependence on financing or service revenue.
Balance-sheet VolatilityThe sharp TTM increase in absolute debt and assets creates substantial uncertainty compared with the prior balance-sheet profile. Deeply negative returns on equity also show weak capital efficiency, making financial planning and evaluation of sustainable funding capacity more difficult.
Cel-Sci News
LSR FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was €0.76 and its highest was €9.70 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is €32.65M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Dec 23, 2026 which is in 81 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Aug 17, 2026. The company reported -€0.417 earnings per share for the quarter.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,588,987 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -€0.417 in its last earnings report. Following the earnings report the stock price went up 5.042%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in DE:LSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cel-Sci Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
DE:LSR Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €121.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.